Bruker Corporation $BRKR Shares Sold by Tredje AP fonden

Tredje AP fonden lessened its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 48.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,760 shares of the medical research company’s stock after selling 12,959 shares during the period. Tredje AP fonden’s holdings in Bruker were worth $447,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd purchased a new position in shares of Bruker during the 2nd quarter valued at about $192,735,000. AQR Capital Management LLC grew its holdings in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares during the period. Sculptor Capital LP raised its position in Bruker by 18.3% during the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after acquiring an additional 476,363 shares in the last quarter. Brown Advisory Inc. boosted its position in Bruker by 13.9% in the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after purchasing an additional 336,026 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. boosted its position in Bruker by 61.6% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock worth $67,909,000 after purchasing an additional 796,510 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. JPMorgan Chase & Co. raised their price target on shares of Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. UBS Group reaffirmed a “neutral” rating and issued a $49.00 price objective on shares of Bruker in a report on Friday, February 13th. Citigroup lowered their target price on shares of Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a research note on Friday, February 13th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $50.38.

Bruker Trading Up 3.3%

Shares of Bruker stock opened at $39.56 on Tuesday. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $56.22. The firm has a market capitalization of $6.01 billion, a PE ratio of -263.73, a P/E/G ratio of 2.29 and a beta of 1.19. The firm’s 50-day moving average price is $46.03 and its 200 day moving average price is $40.67.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm had revenue of $977.20 million during the quarter, compared to analysts’ expectations of $964.61 million. During the same quarter last year, the business earned $0.76 EPS. The business’s revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s payout ratio is -133.33%.

Insider Activity

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total transaction of $98,400.00. Following the completion of the sale, the vice president owned 128,443 shares of the company’s stock, valued at $6,319,395.60. This represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 27.30% of the stock is owned by insiders.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.